Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Malignant Tumor of Ill-defined Site 1Lung Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Radiotherapy 5Paclitaxel 4Carboplatin 4Pemetrexed 3Docetaxel 3Cisplatin 3Taxes 2Gemcitabine 2Bevacizumab 2satraplatin 1pegfilgrastim 1Watchful Waiting 1Vinorelbine 1Thalidomide 1Sorafenib 1Selenomethionine 1Radiotherapy, Conformal 1Radiation 1Pharmacogenomic Testing 1Neoadjuvant Therapy 1Filgrastim 1Etoposide 1Erlotinib Hydrochloride 1Early Intervention, Educational 1Chemotherapy, Adjuvant 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma, Bronchiolo-Alveolar × Pharmacogenomic Testing × Clear all
NCT01208064 2018-07-12

Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Terminated
102 enrolled
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡